Show news: from last 30 days (default), 60 days, 90 days, last visit or all

Cochrane review: ketamine as an adjuvant to opioids for cancer pain

29th November 2017

This update (last updated in 2012) has been published in full on-line. The authors conclude that there is still insufficient evidence to assess the benefits and harms of ketamine as an adjuvant to opioids for the relief of refractory cancer pain. The evidence is very low quality. Rapid dose escalation of ketamine to high-dose (500mg) does not appear to have clinical benefit and may be associated with serious undesirable effects. More randomised controlled trials regarding specific low-dose ketamine clinical regimens in current use are needed.

click here to view